Новые азотсодержащие производные андростана, подавляющие пролиферацию клеток карциномы простаты

##plugins.themes.bootstrap3.article.sidebar##

pdf html html (English)
Опубликован: Oct 1, 2024
DOI: https://doi.org/10.18097/BMCRM00241
Ключевые слова:
молекулярный докинг; антипролиферативная активность; синтез производных стероидов; ингибиторы СYP17А1; клетки карциномы простаты; азотсодержащие стероидные производные

##plugins.themes.bootstrap3.article.main##

А.С. Латышева
Научно-исследовательский институт биомедицинской химии имени В.Н. Ореховича, 119121, Москва, Погодинская ул., 10
А.Ю. Мишарин
Научно-исследовательский институт биомедицинской химии имени В.Н. Ореховича, 119121, Москва, Погодинская ул., 10
А.В. Веселовский
Научно-исследовательский институт биомедицинской химии имени В.Н. Ореховича, 119121, Москва, Погодинская ул., 10
Г.Е. Морозевич
Научно-исследовательский институт биомедицинской химии имени В.Н. Ореховича, 119121, Москва, Погодинская ул., 10
Р.А. Новиков
Институт молекулярной биологии имени В.А. Энгельгардта Российской академии наук, 119991, Москва, ул. Вавилова, 32
В.А. Золотцев
Научно-исследовательский институт биомедицинской химии имени В.Н. Ореховича, 119121, Москва, Погодинская ул., 10

Аннотация

Синтезированы производные 3β-гидроксиандроста-5,16-диена и 3β-гидроксиандрост-5-ена, содержащие при С-17 2-оксазолиновый, 2-бензоксазоловый и 2-бензимидазоловый заместитель. Докинг синтезированных соединений в активный центр CYP17A1 прогнозировал их высокое сродство к ферменту. Из 6 новых соединений 5 подавляли пролиферацию клеток карциномы простаты LNCaP и PC-3, причём активность оксазолинового и бензимидазолового производных андроста-5,16-диена существенно превосходила активность известных противораковых агентов абиратерона и галетерона.

##plugins.themes.bootstrap3.article.details##

Как цитировать
Латышева A., Мишарин A., Веселовский A., Морозевич G., Новиков R., & Золотцев V. (2024). Новые азотсодержащие производные андростана, подавляющие пролиферацию клеток карциномы простаты. Biomedical Chemistry: Research and Methods, 7(3), e00241. https://doi.org/10.18097/BMCRM00241
Выпуск
Том 7 № 3 (2024)
Раздел
ЭКСПЕРИМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯ

Библиографические ссылки

  1. Ling, Y.Z., Li, J.S., Liu, Y., Kato, K., Klus, G.T., Brodie, A. (1997) 17-Imidazolyl, pyrazolyl, and isoxazolyl androstene derivatives. Novel steroidal inhibitors of human cytochrome C17,20-lyase (P450(17 alpha). J. Med. Chem., 40(20), 3297–3304. DOI
  2. Njar, V.C.O., Kato, K., Nnane, I.P., Grigoryev, D.N., Long, B.J., Brodie, A. (1998) Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17 alpha-hydroxylase-C17,20-lyase (P450(17) alpha): Potential agents for the treatment of prostate cancer. J. Med. Chem., 41(6), 902–912. DOI
  3. Njar, V.C., Brodie, A.M. (1999) Inhibitors of 17alphahydroxylase/ 17,20-lyase (CYP17): Potential agents for the treatment of prostate cancer. Curr. Pharm. Des., 5(3), 163–180.
  4. Zhu, N., Ling, Y., Lei, X., Handratta, V., Brodie, A.M.H. (2003) Novel P450(17alpha) inhibitors: 17-(2′-oxazolyl)- and 17-(2′-thiazolyl)-androstene derivatives. Steroids, 68(7–8), 603–611. DOI
  5. Bruno, R.D., Njar, V.C. (2007) Targeting cytochrome P450 enzymes: A new approach in anti-cancer drug development. Bioorg Med. Chem., 15(15), 5047–5060. DOI
  6. Baston, E., Leroux, F.R. (2007) Inhibitors of steroidal cytochrome P450 enzymes as targets for drug development. Recent. Pat. Anticancer. Drug Discov., 2(1), 31–58. DOI
  7. Potter, G.A., Barrie, S.E., Jarman, M., Rowlands, M.G. (1995) Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): Potential agents for the treatment of prostatic cancer. J. Med. Chem., 38(13), 2463–2471. DOI
  8. Handratta, V.D., Vasaitis, T.S., Njar, V.C., Gediya, L.K., Kataria, R., Chopra, P., Newman, D. Jr., Farquhar, R., Guo, Z., Qiu, Y., Brodie, A.M. (2005) Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: Synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J. Med. Chem., 48(8), 2972–2984. DOI
  9. Njar, V.C., Brodie, A.M. (2015) Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer. J. Med. Chem., 58(5), 2077–2087. DOI
  10. Hartmann, R.W., Ehmer, P.B., Haidar, S., Hector, M., Jose, J., Klein, C.D., Seidel, S.B., Sergejew, T.F., Wachall, B.G., Wächter, G.A., Zhuang, Y. (2002) Inhibition of CYP 17, a new strategy for the treatment of prostate cancer. Arch. Pharm. (Weinheim), 335(4), 119–128. DOI
  11. Salvador, J.A., Pinto, R.M., Silvestre, S.M. (2013) Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases. J. Steroid Biochem. Mol. Biol., 137, 199–222. DOI
  12. Salvador, J.A.R., Moreira, V.M., Silvestre, S.M. (2013) Steroidal CYP17 Inhibitors for Prostate Cancer Treatment: From Concept to Clinic. Chapter 12 In: Advances in Prostate Cancer (Hamilton, G., ed.); InTech, 704 p. DOI
  13. Bird, I.M., Abbott, D.H. (2016) The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature. J. Steroid Biochem. Mol. Biol., 163, 136–146. DOI
  14. Stulov, S.V., Misharin, A.Y. (2013) Synthesis of steroids with nitrogen-containing substituents in ring D. Chem. Heterocycl. Comp., 48, 1431–1472. DOI
  15. Singh, R., Panda, G. (2013) An overview of synthetic approaches for heterocyclic steroids, Tetrahedron, 69(14), 2853–2884. DOI
  16. Owen, C.P. (2009) 17alpha-hydroxylase/17,20-lyase (p450(17alpha)) inhibitors in the treatment of prostate cancer: A review. Anticancer Agents Med. Chem., 9(6), 613–626. DOI
  17. Vasaitis, T.S., Bruno, R.D., Njar, V.C. (2011) CYP17 inhibitors for prostate cancer therapy. J. Steroid Biochem. Mol. Biol., 125(1–2), 23–31. DOI
  18. Latysheva, A.S., Misharin, A.Yu. (2018) Steroidal inhibitors of CYP17A1 — the template for novel anti-cancer agents development. Biomedical Chemistry: Research and Methods, 1(2), e00020. DOI
  19. Latysheva, A.S., Zolottsev, V.A., Pokrovsky, V.S., Khan, I.I., Misharin, A.Y. (2021) Novel nitrogen containing steroid derivatives for prostate cancer treatment. Curr. Med. Chem., 28(40), 8416–8432. DOI
  20. Huo, H., Li, G., Shi, B., Li, J. (2022) Recent advances on synthesis and biological activities of C-17 aza-heterocycle derived steroids. Bioorg. Med. Chem., 69, 116882. DOI
  21. Kostin, V.A., Zolottsev, V.A., Kuzikov, A.V., Masamrekh, R.A., Shumyantseva, V.V., Veselovsky, A.V., Stulov, S.V., Novikov, R.A., Timofeev, V.P., Misharin, A.Y. (2016) Oxazolinyl derivatives of [17(20)E]-21-norpregnene differing in the structure of A and B rings. Facile synthesis and inhibition of Cyp17A1 catalytic activity. Steroids, 115, 114–122. DOI
  22. Zolottsev, V.A., Kostin, V.A., Novikov, R.A., Tkachev, Ya.V., Zavialova, M.G., Taratynova, M.O., Latysheva, A.S., Zazulina, O.V., Timofeev, V.P., Misharin, A.Yu. (2018) Synthesis of nitrogen-containing derivatives of 17(20)-pregnenoic, 17β-hydroxypregnanoic, and 17α-hydroxypregnanoic acids as new potential antiandrogens. Russ. Chem. Bull., 67, 667–681. DOI
  23. Kostin, V.A., Latysheva, A.S., Zolottsev, V.A., Tkachev, Ya.V., Timofeev, V.P., Kuzikov, A.V., Shumyantseva, V.V., Morozevich, G.E., Misharin, A.Yu. (2018) Oxazoline derivatives of [17(20)E]-21- norpregnene – inhibitors of CYP17A1 activity and proliferation of prostate carcinoma cells. Russ. Chem. Bull., 67, 682–687. DOI
  24. Zolottsev, V.A., Tkachev, Y.V., Latysheva, A.S., Kostin, V.A., Novikov, R.A., Timofeev, V.P., Morozevich, G.E., Kuzikov, A.V., Shumyantseva, V.V., Misharin, A.Y. (2018) Comparison of [17(20)E]-21-norpregnene oxazolinyl and benzoxazolyl derivatives as inhibitors of CYP17A1 activity and prostate carcinoma cells growth. Steroids, 129, 24-34. DOI
  25. Staunton, J., Eisenbraun, E.J. (1962) 3β-Acetoxyetienic acid [3β-Acetoxy-5-androstene-17β-carboxylic acid]. Org. Synth., 42, 4. DOI
  26. Trott, O., Olson, A.J. (2010) AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem., 31(2), 455–461. DOI:10.1002/jcc.21334
  27. Salentin, S., Schreiber, S., Haupt, V.J., Adasme, M.F., Schroeder, M. (2015) PLIP: Fully automated protein-ligand interaction profiler. Nucleic Acids Res., 43(1), 443–447. DOI
  28. Mosmann, T. (1983) Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65(1–2), 55–63. DOI
  29. Grossebrummel, H., Peter, T., Mandelkow, R., Weiss, M., Muzzio, D., Zimmermann, U., Walther, R., Jensen, F., Knabbe, C., Zygmunt, M., Burchardt, M., Stope, M.B. (2016) Cytochrome P450 17A1 inhibitor abiraterone attenuates cellular growth of prostate cancer cells independently from androgen receptor signaling by modulation of oncogenic and apoptotic pathways. Int. J. Oncol., 48(2), 793–800. DOI
  30. Bruno, R.D., Gover, T.D., Burger, A.M., Brodie, A.M., Njar, V.C. (2008) 17alpha-Hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response. Mol. Cancer Ther., 7(9), 2828–2836. DOI